-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $37

Benzinga·12/12/2025 17:22:49
語音播報
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $36 to $37.